Compositions and methods for diagnosing and treating cancers

• US 20070092529A1
• Filed: 08/23/2006
• Published: 04/26/2007
• Est. Priority Date: 05/20/2003
• Status: Abandoned Application

• Current Assignee: Wyeth (Pfizer Inc.)
• Original Assignee: Wyeth (Pfizer Inc.)
• Inventors: Liu, Wei, Slonim, Donna, Be, Xiaobing, Howes, Steve
• Application Number:
  US11/509,413
• Publication Number:
  US 20070092529A1
• Time in Patent Office: Days
• US Class Current: 424/185.1
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/713 Double-stranded nucleic acids or oligonucleotides
• CPC Class Codes: A61K 35/17 Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes when activated by a specific antigen A61K39/00
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/11 Antisense
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/136 Screening for pharmacological compounds
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA
• CPC Class Codes: G01N 33/57492 involving compounds localized on the membrane of tumor or cancer cells

Abstract

Compositions and methods for diagnosing, monitoring, or treating cancers. Genes encoding transmembrane proteins that are over-expressed in colon, lung, breast, prostate, liver, stomach, esophagus, or kidney cancer tissues are identified. These transmembrane genes can be used as biological markers for the detection or diagnosis of cancers. These genes can also serve as targets for cancer therapeutics. In addition, these genes can also be used for screening for anti-cancer drugs.

Claims

1-14. -14. (canceled)

15. A method comprising:

detecting an expression profile of at least one gene in a biological sample of a mammal of interest, and comparing said expression profile to a reference expression profile of said at least one gene, wherein said at least one gene is selected from the group consisting of ABCC4, C20orf103, CACNA1D, CDH6, CST, ENPP3, FLJ11856, GPR54, HAVCR1, SLC6A3, SLC30A4, TRG@, and TRPM4.

16. The method of claim 15, wherein said mammal of interest is a human who has at least one cancer selected from the group consisting of colon cancer, lung cancer, breast cancer, prostate cancer, liver cancer, kidney cancer, stomach cancer, and esophageal cancer, and said biological sample is a cancer tissue sample.

17. The method of claim 16, wherein said gene is selected from the CRTPGs in Table 1b that correspond to said one cancer.

18. The method of claim 17, wherein said reference expression profile is an average expression profile of said at least one gene in biological samples of cancer-free humans.

19. The method of claim 18, wherein said expression profile and said reference expression profile are determined by RT-PCR, nucleic acid arrays, or immunoassays.

20. (canceled)